{
    "clinical_study": {
        "@rank": "104407", 
        "brief_summary": {
            "textblock": "This protocol provides for the availability of spiramycin under compassionate-use conditions\n      for the treatment of chronic diarrhea due to cryptosporidium in patients with a compromised\n      immune system, thus deriving additional information regarding its safety and efficacy\n      profile."
        }, 
        "brief_title": "Open-Label \"Compassionate\" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients", 
        "condition": [
            "Cryptosporidiosis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cryptosporidiosis", 
                "Diarrhea"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with known sensitivity to macrolide antibiotics are excluded. Consideration must\n        be given to the fact that spiramycin is a macrolide antibiotic and, therefore, may have\n        the potential to induce hepatotoxicity.\n\n          -  Patients with a compromised immune system may have hepatic abnormalities or even\n             hepatitis. If the benefit-to-risk ratio does not favor the use of spiramycin, the\n             patients must be excluded from the study.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other investigational drugs.\n\n        Patients with known sensitivity to macrolide antibiotics are excluded. Consideration must\n        be given to the fact that spiramycin is a macrolide antibiotic and, therefore, may have\n        the potential to induce hepatotoxicity.\n\n          -  Patients with a compromised immune system may have hepatic abnormalities or even\n             hepatitis. If the benefit-to-risk ratio does not favor the use of spiramycin, the\n             patients must be excluded from the study.\n\n        Prior Medication:\n\n        Excluded within 7 days of study entry:\n\n          -  Other investigational drugs.\n\n        Diagnosis of chronic diarrhea due to cryptosporidiosis and a compromised immune system but\n        not limited to patients with AIDS.\n\n          -  Patients receiving chemotherapy for a malignancy.\n\n          -  Patients who are iatrogenically immune-suppressed following organ transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002062", 
            "org_study_id": "011A", 
            "secondary_id": "CCA 901"
        }, 
        "intervention": {
            "intervention_name": "Spiramycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Spiramycin"
        }, 
        "keyword": [
            "Spiramycin", 
            "AIDS-Related Opportunistic Infections", 
            "Immune Tolerance", 
            "Cryptosporidiosis", 
            "Diarrhea", 
            "Drugs, Investigational", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Horsham", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19044"
                }, 
                "name": "Rhone - Poulenc Rorer Pharmaceuticals"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Open-Label \"Compassionate\" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002062"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rhone-Poulenc Rorer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1991"
    }, 
    "geocoordinates": {
        "Rhone - Poulenc Rorer Pharmaceuticals": "40.178 -75.129"
    }
}